	US 11,965,875 B2
	System and method for screening and assessing agents for tumor immunotherapy
Nanhai He, Hangzhou (CN); Youping Wang, Hangzhou (CN); Yang Lu, Hangzhou (CN); and Donghui Yang, Hangzhou (CN)
Assigned to ADLAI NORTYE BIOPHARMA CO. LTD., Hangzhou (CN)
Filed by ADLAI NORTYE BIOPHARMA CO., LTD., Hangzhou (CN)
Filed on May 18, 2021, as Appl. No. 17/323,078.
Claims priority of application No. 202011284771.X (CN), filed on Nov. 17, 2020.
Prior Publication US 2022/0155282 A1, May 19, 2022
Int. Cl. C12N 5/00 (2006.01); G01N 33/50 (2006.01)

CPC G01N 33/5011 (2013.01) [G01N 33/505 (2013.01); G01N 33/5052 (2013.01)]

9 Claims

1. A method of screening an agent for tumor immunotherapy, comprising assessing the effect of an analyte on tumor immune cells, the method comprises the steps of:

i) assessing the effect of the analyte on target cells, when the target cells are T cells;

ii) assessing the effect of the analyte on non-target cells; and

iii) assessing the effect of the analyte on tumor immune infiltration;

wherein step i) comprises:

i-1) assessing the effect of the analyte on the proliferative capacity of immune cell line target cells, and

i-2) assessing the effect of the analyte on the IL-2 expression level of primary immune cell target cells;

wherein after the assessment of step i-1), the assessment result is divided into two levels of positive (+) and negative (−), and the analyte with a negative assessment result is directly determined as a negative analyte without performing any subsequent steps;

step i-2) is continued for the analyte with a positive assessment result in the step i-1), and the assessment result is divided into two levels of positive (+) or negative (−); the analyte with a negative assessment result in step i-2) is directly determined as a negative analyte without performing any subsequent steps;

step ii) comprises assessing the effect of the analyte on the cell viability of immune cell line non-target cells, and/or assessing the effect of the analyte on the cell viability of primary immune cell non-target cells,

iv) determining the analyte with a level of positive (+) assessment after step i-2) as the agent for tumor immunotherapy.